Standard BioTools Inc.
LAB
$1.07
-$0.045-4.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.42% | 65.74% | 77.27% | 34.48% | 87.26% |
| Total Other Revenue | -- | -- | -- | -- | 15.13% |
| Total Revenue | -10.42% | 65.74% | 77.27% | 34.48% | 81.30% |
| Cost of Revenue | -1.40% | 67.30% | 52.73% | 105.05% | 66.32% |
| Gross Profit | -18.39% | 64.00% | 108.54% | -158.16% | 96.95% |
| SG&A Expenses | -17.54% | 76.02% | 54.33% | 58.29% | 120.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.65% | 77.41% | 61.56% | 80.39% | 107.77% |
| Operating Income | 21.79% | -99.49% | -38.78% | -164.05% | -150.83% |
| Income Before Tax | 18.25% | -69.53% | -28.04% | -172.79% | -93.18% |
| Income Tax Expenses | -217.97% | 267.90% | 136.00% | -81.73% | -51.33% |
| Earnings from Continuing Operations | 19.04% | -72.29% | -28.29% | -168.30% | -90.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.04% | -72.29% | -28.29% | -168.30% | -90.92% |
| EBIT | 21.79% | -99.49% | -38.78% | -164.05% | -150.83% |
| EBITDA | 22.12% | -134.39% | -126.32% | -148.59% | -130.03% |
| EPS Basic | 74.12% | 63.31% | 72.67% | 43.31% | -24.79% |
| Normalized Basic EPS | 49.01% | 51.37% | 76.12% | 48.61% | 37.57% |
| EPS Diluted | 74.12% | 64.03% | 73.15% | 43.31% | -24.79% |
| Normalized Diluted EPS | 49.01% | 51.37% | 76.12% | 48.61% | 37.57% |
| Average Basic Shares Outstanding | 28.59% | 369.77% | 369.40% | 373.29% | 271.93% |
| Average Diluted Shares Outstanding | 28.59% | 369.77% | 369.40% | 373.29% | 271.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |